$ESNT

CASALE MARK sold $245K of ESNT

CASALE MARK (Chairman, CEO and President) sold 3,763 shares of Essent Group Ltd. (ESNT) at $65.01 ($0.24M total) on 2026-06-30 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · CASALE MARK
Published Jul 2, 2026, 10:33 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 2, 2026, 10:34 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ESNT
Neutral
medium confidence
Mentioned
$ESNT
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ESNTNeutralLow
01

Why it matters

The disclosure provides confirmation of insider selling activity, but the pre-arranged 10b5-1 plan reduces interpretive weight for near-term price direction.

02

Market read

Traders may monitor for follow-on insider activity, but this specific filing is unlikely to drive a fundamental repricing.

03

What to watch

Check whether there are concurrent insider buys/sales in the same window and whether the plan size/pace is accelerating or consistent with prior filings.

Relevance 3/10Novelty 5/10Timing: new Form 4 filed 2026-07-02 (covers sale dated 2026-06-30)

Background

SEC Form 4 reports an insider transaction for Essent Group Ltd. (ESNT) by Mark Casale (Chairman, CEO, President).

Company-level read

Ticker impact

$ESNTNeutralMedium confidence
Context

Essent Group insider Mark Casale sold 3,763 shares at $65.01 on 2026-06-30 under a pre-arranged 10b5-1 plan, per Form 4.

Expected impact

Likely minimal near-term impact; any reaction would be more about positioning than fundamentals.

Evidence & confidence

The filing is a primary Form 4 disclosure and is company-specific, but it is explicitly tied to a pre-arranged 10b5-1 plan and the share count/value is modest versus typical market cap context.

Market effects

No sector read-through; this is an individual insider transaction with no operational/regulatory catalyst.

None indicated.

None indicated.

Counterpoint

Because it’s a 10b5-1 plan, the sale may reflect scheduled diversification rather than bearish expectations; traders may ignore it unless paired with other negative signals.

Key entities

  • Essent Group Ltd.

    Company whose insider transaction is disclosed on Form 4.

  • Mark Casale

    Chairman, CEO and President who reported the sale.

  • 10b5-1 plan

    Pre-arranged plan that typically makes sales less informative about near-term outlook.

Related articles

$ESNTMedAI 8/10

Essent Group profit rises 7% as new P&C segment grows

Essent Group reported 2Q net income of $189.7 million, or $2.08 per diluted share, up from $177 million, or $1.93, a year earlier. Profit rose as its P&C reinsurance expansion increased premiums. P&C net premiums were $249 million for 1H 2026, and net premiums earned rose to $73 million. Essent expects $320 million written P&C premium in 2026 and declared a 35-cent quarterly dividend.

$ESNTMedAI 8/10

Essent Group (NYSE:ESNT) Delivers Strong Q2 CY2026 Numbers

Essent Group (NYSE:ESNT) reported Q2 2026 revenue of $362.7 million, up 13.6% year on year, beating Wall Street estimates by 9.7%. GAAP profit was $2.08 per share, 19.3% above consensus. The article also cites book value per share growth of about 11.7% over five years and notes the stock rose 2.4% to $67.08 after results.

$ESNTMed

Unilever, Barclays & Shell: Markets live

Unilever (ULVR) shares rose after it upgraded full-year outlook on improving sales. It reported €25.6bn revenue and €4.66bn pre-tax profit for six months to 30 June, with underlying sales up 4.8%. Other FTSE movers included Barclays (BARC) guidance and buyback, Forterra (FORT) results, and Canal+ (CAN) profit jump tied to MultiChoice consolidation.